Monitor the pace and pricing of share sales, as the at-the-market structure allows for opportunistic selling that could pressure the stock price. The offering follows a recent shelf registration, indicating potential for future dilution. The company's going concern warning in its financials adds risk to the capital raise strategy.
Price Chart
Executive Summary
Oncolytics Biotech is conducting an at-the-market offering of up to $75 million in common stock through Jefferies, following a $250 million shelf registration. The company plans to use the proceeds for clinical development of pelareorep and general corporate purposes. This offering follows a recent shelf registration and represents potential future dilution.
Key Facts
- Oncolytics Biotech is offering up to $75 million in common stock through an at-the-market offering with Jefferies
- The offering is part of a $250 million shelf registration filed on April 1, 2026
- Proceeds will fund clinical development of pelareorep, research and development, operating costs, and general corporate purposes
- The offering price is up to $0.96 per share, with an expected issuance of up to 78,125,000 shares
- Investors will experience immediate dilution of $0.59 per share
- The company has a market cap of $103 million and reported net tangible book value of $(3.8) million as of December 31, 2025
Financial Impact
Up to $75 million in gross proceeds with potential for significant dilution
Risk Factors
- Immediate dilution of $0.59 per share for new investors
- Potential for further dilution if the company issues additional shares
- The company's financial statements include an explanatory paragraph about conditions that raise substantial doubt about its ability to continue as a going concern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-039932 |
| Document: 0001104659-26-039932-index-headers.html | 0001104659-26-039932 |
| Document: 0001104659-26-039932-index.html | 0001104659-26-039932 |
| Document: 0001104659-26-039932.txt | 0001104659-26-039932 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access